← All trials
NCT06612814
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2024
- Primary completion
- Oct 30, 2027
- Completion date
- Apr 30, 2028
- First posted
- Sep 25, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 307
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Fudan UniversitySponsor investigator
- Nanjing Medical UniversityCollaborator
- Peking UniversityCollaborator
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
- Nantong UniversityCollaborator
- Dalian Medical UniversityCollaborator
- China Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.